| P/E (FY) | — | Sales (TTM) | $548.5M |
| Earnings (TTM) | $456.9M | ROE | 45.74% |
| Net Margin | 83.30% | ROIC | — |
| Debt / Equity | 0.08 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 8.76% |
| Market Cap | — | Trading Days | 2603 |
| 52W High | 19.50 |
| 52W Low | 9.77 |
| % Off High | −42.56% |
| YTD | −15.98% | 1Y | −37.71% |
| 3Y | −23.91% | 5Y | −73.21% |
| 10Y | −14.57% | Since incept. (ann.) | −1.72% |
| Ann. Volatility (1Y) | 37.73% | Ann. Volatility (3Y) | 53.71% |
| Sharpe (1Y) | −1.08 | Sharpe (3Y) | 0.12 |
| Max Drawdown (1Y) | −48.00% | Max Drawdown (3Y) | −54.13% |
| Beta (3Y, vs SPY) | −0.51 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $124.46B | 32.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
